---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-303004"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2023-12-26T23:59:59+00:00"
generated_at: "2026-06-07T07:31:51.188460+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics draws $25M in new term loans from Oxford Finance

## Summary
- Total borrowings under the Loan Agreement now $50M, after draws of $5M (Dec 2021), $20M (Nov 2022), and this $25M.
- Loan bears floating interest at the greater of 8.25% or 1-Month CME Term SOFR + 8.25% per annum.
- Final maturity date is December 17, 2027; a final fee of 7% of aggregate principal is due at maturity or prepayment.
- Prepayment fee: 3% if within first year after funding, 2% if within second year, none thereafter.
- Proceeds use not specified; lender is Oxford Finance LLC.

## SEC filing metadata
- accession: 0001193125-23-303004
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2023-12-26T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312523303004/0001193125-23-303004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312523303004/d620772d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-303004
- JSON: https://secwatch.observer/filing/0001193125-23-303004.json
- Plain text: https://secwatch.observer/filing/0001193125-23-303004.txt

## Key facts
- Debt Financings
  Vera Therapeutics, Inc. incurred term loan of $25.0 million with Oxford Finance LLC at the greater of (i) 8.25% and (ii) the sum of (a) 1-Month CME Term SOFR and (b) 8 maturing December 17, 2027.
  - Instrument: term loan
  - Principal: $25.0 million
  - Counterparty: Oxford Finance LLC
  - Rate: the greater of (i) 8.25% and (ii) the sum of (a) 1-Month CME Term SOFR and (b) 8
  - Maturity: December 17, 2027
  - Event: incurrence
  source text: On December 22, 2023, Vera Therapeutics, Inc. (the “Company”) drew down an aggregate of $25.0 million in new term loans pursuant to its previously disclosed Loan and Security Agreement, dated December 17, 2021, as amended (the “Loan Agreement”), by and between the Company and Oxford Finance LLC (the “Lender”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831828/000119312523303004/0001193125-23-303004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.